Amgen Inc.

🇺🇸NASDAQ Global Select
Back to all articles
Amgen Inc. stock analysis AMGN overview
Somewhat Bullish +45

Amgen (AMGN) Stock Could Be 2.1% Undervalued After Patent Verdict - simplywall.st

📉 Amgen stock is trading at $344.72, representing a 2.1% undervaluation against a calculated fair value of $352.23.

⚖️ Harbour BioMed secured a jury verdict confirming willful infringement by Amgen and awarded $20.2 million in damages.

📈 Amgen has delivered a 30.33% total shareholder return over the past year and a 68.20% return over three years.

💊 The company's pipeline includes high-margin assets like MariTide for obesity, Repatha for cardiovascular disease, and bispecific T-cell engagers for oncology.

📉 Legal risks persist as the verdict highlights ongoing patent litigation exposure in the biopharmaceutical sector.

⚠️ Revenue faces potential headwinds from tightening drug pricing regulations and competition from biosimilars.

💰 Amgen maintains its status as an established dividend payer with a solid balance sheet structure.

Bullish Signals
  • Amgen stock is trading at $344.72, which is approximately 2.1% below the calculated fair value of $352.23, suggesting a potential buying opportunity.
  • The company has achieved a strong 30.33% total shareholder return over the last year and a 68.20% return over three years, indicating sustained investor confidence.
  • Amgen's late-stage pipeline features high-margin, first-in-class products including MariTide for obesity and Repatha for cardiovascular disease that are poised to drive future growth.
  • The company is classified as an established dividend payer with a solid balance sheet, providing resilience against market volatility.
Risk Factors
  • Amgen was found guilty of willful patent infringement by Harbour BioMed's jury and ordered to pay $20.2 million in damages.
  • Amgen is exposed to potential tightening of drug pricing pressures which could impact future top-line growth and margins.
Full Analysis
Amgen (AMGN) stock is currently trading at $344.72, which a recent analysis suggests is approximately 2.1% undervalued relative to a calculated fair value of $352.23. This valuation assessment follows a significant legal development where Harbour BioMed's jury found Amgen guilty of willful patent infringement, awarding the competitor $20.2 million in damages. Despite the recent legal setback, Amgen has demonstrated strong longer-term momentum with a 30.33% one-year total shareholder return and a 68.20% three-year return. The company's share price has gained 5.21% year-to-date, trading close to analyst price targets while maintaining a solid balance sheet and established dividend status. The bullish thesis relies on Amgen's robust late-stage pipeline featuring high-margin, first-in-class products such as MariTide for obesity and type 2 diabetes, Repatha for cardiovascular health, and multiple bispecific T-cell engagers for oncology. These advancements are expected to drive top-line growth and margin expansion in the coming years. However, investors must weigh these growth prospects against specific risks including potential tightening of drug pricing pressures and the threat of biosimilar competitors eroding revenue from key franchises faster than anticipated. The market sentiment remains split between concerns over legal liabilities and confidence in the pipeline's future potential.